Enhanced local intensified radiation for older adults with glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 hybrid randomized trial comparing dose‑escalated hypofractionated radiotherapy to standard hypofractionated radiotherapy in older adults with newly diagnosed glioblastoma. Eligible participants are age 65 or older with histologically confirmed WHO grade 4 (IDH wild-type) glioblastoma, ECOG performance status 0–2, and enrollment within eight weeks of surgery with central pathology review. Radiation will be delivered either at the standard daily hypofractionated dose or at an increased per‑fraction dose over a short course, and participants will be followed for safety, treatment‑related toxicity, and clinical outcomes. The trial is being conducted across academic and community sites affiliated with the lead institution to capture both efficacy and real‑world delivery data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological confirmation of WHO grade 4 glioblastoma (IDH wild-type by immunohistochemistry or sequencing). Histopathology must be confirmed by central review.
* Newly diagnosed disease, with time elapsed from diagnostic surgery/resection \<8 weeks.
* Age ≥ 65 years old at time of glioblastoma diagnosis
* Adequate functional status as measured by a ECOG Performance Status 0, 1 or 2, at time of enrollment.
* Adequate hematological, renal and hepatic functions as defined by the following required laboratory values obtained within 45 days prior to randomization:

Platelet count ≥ 100 x 10\^9/L (100,000 cells/mm\^3) Serum creatinine ≤ 1.5 times the upper limit of normal Total serum bilirubin ≤ 1.5 times the upper limit of normal ALT (SGPT) \< 2.5 times the upper limit of normal and/or AST (SGOT) \< 2.5 times the upper limit of normal

-Patient may have received corticosteroids, but must be on a stable or decreasing dose for at least 14 days prior to randomization.

Exclusion Criteria:

* Participants with recurrent glioma.
* Participants with evidence of spinal, leptomeningeal, or more distant disease.
* Participants with another active central nervous system malignancies requiring treatment.
* Participants with a second invasive malignancy that is A) incompletely treated or requiring ongoing treatment, or B) reasonably anticipated to be associated with a median overall survival of less than 1 year based on population-level data for the specified disease site and stage.
* Participants with any other major medical illnesses or psychiatric treatments that in the treating physician's opinion will prevent administration or completion of protocol therapy.
* Participants with inadequate mental capacity to provide informed consent
* Participants who cannot receive gadolinium
* Participants who have undergone prior head and neck or cranial radiation or radiation to any other site previously that would be reasonably anticipated to result in a significant overlap in radiation fields.
* Participants who have received systemic or radiosensitizing therapy for a prior head and neck or central nervous system malignancy or any investigational cancer drug for glioblastoma prior to randomization.
* Participants who have received or plan to receive any other form of non-surgical local or field treatment overlapping with the anticipated radiation field.
* Patients with a serious active infection (such as a wound infection requiring parenteral antibiotics) or other acute medical conditions at the time of randomization that would impair the ability of the patient to receive protocol treatment.

Where it's running

• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting
• Dana-Farber Brigham Cancer Center, Milford Hospital
  Milford, Massachusetts, United States Recruiting
• Dana-Farber Brigham Cancer Center, South Shore Hospital
  South Weymouth, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Rifaquat Rahman, MD
• Email: rrahman@bwh.harvard.edu
• Phone: 617-732-6682

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Personalized Targeted Glioblastoma Therapies Guided by Ex Vivo Drug Screening

  This trial tests whether using a patient’s own tumor cells to screen drugs can guide a personalized treatment plan for people with newly diagnosed glioblastoma undergoing short-course radiotherapy.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT07627334

• LITT for ultra-early GBM recurrence within 1 week of pre-radiation planning

  This study tests whether a minimally invasive laser treatment can destroy an early GBM recurrence without delaying planned radiotherapy and chemotherapy.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT07616986

• Combined intracranial and intravenous NK cell therapy for malignant brain tumors

  This trial will test whether giving adults with recurrent malignant brain tumors their own expanded and activated natural killer (NK) cells into the tumor site and into the bloodstream is safe and feasible.

  Recruiting at 3 sites Peking University Third Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07552233

• Preventive intrathecal thiotepa with standard chemoradiation for high‑risk glioblastoma

  This trial tests whether adding six weekly intrathecal injections of thiotepa to standard chemoradiation can lower leptomeningeal spread and improve outcomes for adults with newly diagnosed GBM that contacts the subventricular zone or had ventricular entry during surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07511725

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.